RALEIGH, N.C.--(BUSINESS WIRE)--Respirics Inc. announced today that it has decided to divest its assets relating to MD Turbo®. MD Turbo was cleared by the FDA for marketing in 2005 and was launched in the U.S. last year. MD Turbo, the company’s first commercial device, is a companion product designed to assist patients who use pressurized metered dose inhalers (pMDI) for asthma and COPD; the incidence of these diseases in the US alone is over 40 million. MD Turbo solves two major challenges patients have with proper pMDI use: coordination of inhaler actuation with patient inhalation and accounting for how much medication is in an inhaler at any given time.
